Sanofi S.A.
Pharmaceuticals and BiotechnologyFounded 2004- Updated July 2025
Reviewed by Swet Parvadiya
Last reviewed: July 2025
CorpDigest
Sanofi S.A.
Financial Performance
Last reviewed: July 2025 · By Swet Parvadiya
Revenue
$44.6B
Market Cap
$107.8B
Net Income
$6.2B
Employees
76,493
Dupixent's $14.3 billion in FY2024 sales exceeded the total annual revenue of most mid-cap pharmaceutical companies — generated by a single drug that Sanofi co-developed with Regeneron under a collaboration structure initiated in 2007. The Q3 2025 quarterly milestone of $4 billion in global Dupixent sales (and $3 billion in US quarterly sales) for the first time demonstrates the drug's continued growth trajectory even at significant scale. Total revenue grew from $40.8 billion in 2023 to $44.6 billion in 2024, with 2025 projected at $45.9 billion — growth driven primarily by Dupixent expansion as the drug adds patients across its seven approved indications. Net income of $6.2 billion on $44.6 billion in FY2024 revenue produces a 13.9 percent net margin, below the pharmaceutical industry's top-quartile margins because the heavy R&D investment and collaboration profit-sharing with Regeneron reduce the economic return that appears in Sanofi's own income statement. FY2024 R&D expenses reached $8.1 billion — a 14.6 percent increase from 2023 and the company's largest annual R&D investment in history. That urgency reflects the central financial vulnerability: $14.3 billion in Dupixent sales in a portfolio of $44.6 billion means the pipeline must produce significant revenue before Dupixent faces biosimilar competition, which becomes possible as patent protection periods expire in key markets. The Opella separation removes $4.9 billion in consumer healthcare revenue and is projected to drive operating margins toward 32 percent for the remaining pure-play biopharma entity. A 32 percent operating margin on the post-separation revenue base, combined with Dupixent's growth trajectory and the Blueprint Medicines pipeline, represents the financial argument for Sanofi's transformation from diversified pharmaceutical company to focused biopharma.
Revenue Trend Analysis
YoY Change
+3%
2-Year CAGR
+6%
Peak Year
2025
Trend
Consistent Growth
Sanofi S.A. has reported revenue across 3 fiscal years, compounding at +6% annually over 2 years. The most recent year saw a 3% increase versus the prior year. Revenue peaked in 2025 at $45.9B. Out of 2 reported periods, 2 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $45.9B | — | +3.0% |
| FY2024 | $44.6B | $6.2B | +9.1% |
| FY2023 | $40.8B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Sanofi reported revenue of 41.1 billion euros for fiscal 2024, equivalent to approximately $44.6 billion at average exchange rates, up 4 percent at constant currencies from 2023. Specialty Care, anchored by Dupixent and the rare-disease franchises, contributed roughly 21 billion euros and grew 25 percent at constant currencies. Vaccines contributed approximately 7.4 billion euros, with strong growth in Beyfortus and influenza vaccines partially offset by the wind-down of COVID-19 supply contracts. General Medicines contributed roughly 13.7 billion euros, declining at low single digits as legacy primary care brands continued to face generic competition. Consumer Healthcare contributed approximately 5.3 billion euros and was reported through October 2024 inside Sanofi's results before the Opella majority-stake sale. By region, the United States represented approximately 47 percent of 2024 revenue, Europe approximately 22 percent, and the rest of the world about 31 percent. The 4 percent growth marks a significant acceleration relative to the 2014 to 2019 period when Sanofi posted essentially flat revenue, and management has guided to mid-single-digit constant-currency revenue growth through 2025 driven by Dupixent expansion into COPD, the launch of new vaccines, and the rare-disease pipeline.
Sanofi's market capitalization stood at approximately 107 billion euros, or roughly $116 billion, in late 2025, placing it among the top five European pharmaceutical companies by market value behind Novo Nordisk, AstraZeneca, Roche, and Novartis. The share price has historically been weighed down by the so-called French pharma discount, reflecting investor concerns about French government interference in capital allocation, French labor laws constraining restructuring, and the company's complex post-merger legacy. Shares are dual-listed on Euronext Paris under SAN and on Nasdaq via American Depositary Receipts under SNY. The 2023 capital markets day in which CEO Paul Hudson reset Sanofi's medium-term growth ambition and signaled the Opella separation led to a 19 percent single-day share decline on October 27, 2023, removing roughly 18 billion euros of market capitalization. The stock has since recovered substantially as Dupixent's COPD approval, the Beyfortus launch, and the announcement of a 5 billion euro share buyback in late 2024 lifted sentiment. Sanofi initiated an additional buyback program in 2025 funded by Opella proceeds. The dividend has been increased annually for more than three decades, supporting a yield typically between 3 and 4 percent.
Sanofi reported business operating income of approximately 12.4 billion euros in 2024, representing a business operating margin of roughly 30 percent of net sales. Business net income, the company's preferred non-GAAP measure roughly comparable to adjusted earnings, was approximately 9.4 billion euros, or 7.49 euros per share. GAAP net income was lower at approximately 5.7 billion euros, with the gap driven by amortization of intangibles from past acquisitions, restructuring charges, and non-recurring items. Sanofi's gross margin sits in the high 60s percent range, lower than US pharmaceutical peers due to a higher mix of vaccines and lower-priced general medicines, partially offset by the high gross margin on Dupixent. R and D as a percentage of revenue rose to roughly 18 percent in 2024 versus 14 percent at the start of CEO Paul Hudson's tenure in 2019, reflecting a deliberate strategy to reinvest in late-stage biologics. Sanofi has guided to business operating margin in the low 30s percent range by 2025, with the Opella separation removing some lower-margin consumer brands and intensifying the mix toward higher-margin specialty medicines and vaccines.
Sanofi employed approximately 83,000 people globally as of the end of 2024, distributed across more than 70 countries with the largest concentrations in France, the United States, and Germany. France alone hosts approximately 18,000 employees, reflecting Sanofi's status as the largest pharmaceutical employer in the country and the political sensitivity that has historically constrained restructuring. The US workforce of roughly 13,000 is centered in Cambridge, Massachusetts and Bridgewater, New Jersey, supporting both Specialty Care commercial and the Genzyme inheritance. The headcount has trended modestly downward since the 2017 peak of approximately 106,000 as Sanofi divested animal health to Boehringer Ingelheim in 2017 for 11.4 billion euros worth of consumer assets, spun off Euroapi in 2022, and prepared the Opella separation, each removing several thousand employees from the consolidated total. The Opella divestiture in 2024 to 2025 transitioned approximately 11,000 employees to the new consumer healthcare standalone entity, although Sanofi retains a substantial minority stake. Sanofi has been steady in its commitment to maintain French manufacturing and R and D footprints despite restructuring elsewhere, a recurring point in public statements by successive French governments.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Sanofi S.A. Revenue & Financials." CorpDigest, https://corpdigest.com/company/sanofi/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Sanofi S.A. reported $46B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/sanofi/financials" target="_blank" rel="noopener">CorpDigest — Sanofi S.A. financials</a></div>